Mostrando 1,221 - 1,240 Resultados de 84,353 Para Buscar '"HR"', tiempo de consulta: 0.54s Limitar resultados
  1. 1221
  2. 1222
    “…BACKGROUND: The objective of the IMPROVE study was patients’ preference for either endocrine-based therapy or combined chemo- and anti-angiogenic therapy in advanced HR-positive/HER2-negative breast cancer. METHODS: In this randomized, cross-over phase IV study, 77 patients were recruited in 26 sites in Germany. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  3. 1223
  4. 1224
  5. 1225
  6. 1226
  7. 1227
  8. 1228
  9. 1229
  10. 1230
  11. 1231
  12. 1232
  13. 1233
  14. 1234
  15. 1235
  16. 1236
  17. 1237
  18. 1238
    “…We previously identified a fusion inhibitory peptide (HR2P-M2) targeting the MERS-CoV S2 protein HR1 domain and a highly potent neutralizing monoclonal antibody (m336) specific to the S1 spike protein receptor-binding domain (RBD). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  19. 1239
  20. 1240
    “…BACKGROUND: Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) has become the commonest first-line treatment of hormonal receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC). However, therapy is quite individualized after progression of disease (PD) when CDK4/6i fails. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
Herramientas de búsqueda: RSS